The 2023 Diabetic Kidney Disease (DKD) Fact Sheet in Korea highlights the prevalence and management of DKD among patients with diabetes in South Korea. Data from the Korea National Health and Nutrition Examination Survey (KNHANES) and the Korean National Health Insurance Service (NHIS) show that 25.4% of patients with diabetes aged ≥30 years have DKD, with 22.0% having albuminuria and 6.7% having low eGFR. DKD is a significant risk factor for cardiovascular morbidity and mortality, and its prevalence has been increasing over the past decade. Patients with DKD have higher rates of comorbidities such as hypertension, dyslipidemia, and central obesity, but lower control rates for these conditions. Renin-angiotensin system (RAS) blockers are used in 70% of DKD patients, while sodium glucose cotransporter 2 (SGLT2) inhibitors are prescribed to 5.9% of DKD patients. The prevalence of diabetes-related end-stage kidney disease (ESKD) has also increased, particularly in older adults. The study emphasizes the need for intensive management of diabetes and comorbidities to prevent advanced stages of chronic kidney disease (CKD) and cardiovascular disease. The findings suggest that DKD is a major public health issue in South Korea, requiring further research and improved management strategies.The 2023 Diabetic Kidney Disease (DKD) Fact Sheet in Korea highlights the prevalence and management of DKD among patients with diabetes in South Korea. Data from the Korea National Health and Nutrition Examination Survey (KNHANES) and the Korean National Health Insurance Service (NHIS) show that 25.4% of patients with diabetes aged ≥30 years have DKD, with 22.0% having albuminuria and 6.7% having low eGFR. DKD is a significant risk factor for cardiovascular morbidity and mortality, and its prevalence has been increasing over the past decade. Patients with DKD have higher rates of comorbidities such as hypertension, dyslipidemia, and central obesity, but lower control rates for these conditions. Renin-angiotensin system (RAS) blockers are used in 70% of DKD patients, while sodium glucose cotransporter 2 (SGLT2) inhibitors are prescribed to 5.9% of DKD patients. The prevalence of diabetes-related end-stage kidney disease (ESKD) has also increased, particularly in older adults. The study emphasizes the need for intensive management of diabetes and comorbidities to prevent advanced stages of chronic kidney disease (CKD) and cardiovascular disease. The findings suggest that DKD is a major public health issue in South Korea, requiring further research and improved management strategies.